Journal of Contemporary Brachytherapy

Abstract

6/2022 vol. 14
Case report

Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse

Guillaume Beziat 1
,
Suzanne Tavitian 1
,
Francois-Xavier Arnaud 2
,
Françoise Izar 3
,
Justine Attal 3
,
Cécile Borel 1
,
Christian Recher 1
,
Anne Ducassou 3
  1. Hematology Department, Institut Universitaire du Cancer de Toulouse – Oncopole, Centre Hospitalier Universitaire de Toulouse, F-31000 Toulouse, France
  2. Engineering and Medical Physics Department, Institut Universitaire du Cancer de Toulouse – Oncopole, Institut Claudius Regaud, F-31000 Toulouse, France
  3. Radiation Oncology and Brachytherapy Department, Institut Universitaire du Cancer de Toulouse – Oncopole, Institut Claudius Regaud, F-31000 Toulouse, France
J Contemp Brachytherapy 2022; 14, 6: 601–604
DOI: https://doi.org/10.5114/jcb.2022.123980
Online publish date: 2022/12/30
View full text
Acute myeloid leukemia (AML) may extend to extra-medullary sites at diagnosis or at relapse, either isolated or associated with bone marrow disease. Granulocytic sarcoma of uterine cervix is rare, and there is no established treatment for this disease. Two cases of uterine cervix-limited AML relapse showed that brachytherapy may be an effective therapeutic option in this setting along with chemotherapy, with good tolerance.

Keywords

acute myeloid leukemia, brachytherapy, granulocytic sarcoma

Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications